A new biotech tackling IBD joins a race against Lilly and Gilead for a promising pill

Ensho wants to develop an oral α4β7 inhibitor that could be a breakthrough treatment for inflammatory bowel disease by controlling how T cells regulate inflammatory responses in the gut.